It takes tenacity to push a biotechnology agenda forward. Costly, time consuming and inherently complex, research and development projects are fraught with uncertainty. The second quarter financial report of Pharmaceutical Medical makes clear the Company is moving forward despite limited capital and a daunting work load shared by a small team.
The Company has partnered with the University of Queensland’s commercial arm UniQuest Pty. to pursue preventative and palliative therapies based on natural and organic substances. The research team is working on an ambitious agenda of four projects, and progress continues for each.
Notably, work on the non-opioid analgesic has given rise to new patent applications with the Australian Patent Office related to cyclic peptides and their use in pain management. UniQuest, the University of Queensland’s commercializing arm and PreveCeutical’s R&D partner, has a world reputation for commercial success. UniQuest has facilitated over 700 patent patents, of which 87 were granted in the U.S., and spun out more than 70 start-up companies.
A new report provides more details on recent fundamental progress. Click the image below to access the 10-page report.
Please note the important disclosures and disclaimers at the end of every Crystal Equity Research report.